Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TYR | P14679 | 1/20 | 0.41 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20155899 | 0.68 | SMN1; SMN2 (0.38) | SMN1; SMN2ALDH1A1CA2POLBTYR | |
| SCHEMBL7942358 | 0.67 | ALDH1A1 (0.56) | SMN1; SMN2ALDH1A1CA2POLBTYR | |
| SCHEMBL31483671 | 0.64 | ALDH1A1 (0.52) | SMN1; SMN2ALDH1A1CA2POLBTYR | |
| SCHEMBL27800581 | 0.63 | SMN1; SMN2 (0.56) | SMN1; SMN2ALDH1A1CA2POLBTYR | |
| SCHEMBL27704633 | 0.63 | SMN1; SMN2 (0.50) | SMN1; SMN2ALDH1A1CA2POLBTYR | |
| SCHEMBL7047479 | 0.62 | ALDH1A1 (0.62) | SMN1; SMN2ALDH1A1CA2POLBTYR | |
| Butylated Hydroxytoluene SCHEMBL28034277 | 0.62 | SMN1; SMN2 (0.95) | SMN1; SMN2ALDH1A1CA2POLBTYR | |
| SCHEMBL11647740 | 0.62 | SMN1; SMN2 (0.54) | SMN1; SMN2ALDH1A1CA2POLBTYR | |
| SCHEMBL434782 | 0.61 | ALDH1A1 (0.59) | SMN1; SMN2ALDH1A1CA2POLBTYR | |
| SCHEMBL5857102 | 0.60 | ALDH1A1 (0.52) | SMN1; SMN2ALDH1A1CA2POLBTYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180134675-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134675-A1 | MAGL INHIBITORS | MAG, MAGI3, MGLL | SMN1; SMN2 1770/4885ALDH1A1 4349/4885CA2 950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.